Sign inJoin waitlistJoin the waitlist

Manu Pandey

Physician · University of Oklahoma College of Medicine

Credentials: · ·

History

University of Oklahoma College of Medicine
2023–Present

Hematology and Medical Oncology
University at Buffalo School of Medicine
2018–2021
Internal Medicine
University at Buffalo School of Medicine
2015–2018
Bachelor of Medicine, Bachelor of Surgery
2010–2014

Research

Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor…
Clinical Cancer Research · 2021 · Co-first of 19 authors · 132 citations
Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies
Nature Communications · 2024 · 40 citations
Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies
Review · British Journal of Clinical Pharmacology · 2020 · 31 citations

Marc Ernstoff
5 papers
Mohamad Khawandanah
5 papers
Eunice Wang
4 papers
Jennifer Chakrabarty
4 papers
Shipra Gandhi
4 papers · 2 as a fellow
Adam Asch
3 papers
Sami Ibrahimi
3 papers
Taha Al-Juhaishi
3 papers
Alexandra Arteaga
2 papers
Anurekha Hall
2 papers
Cameron MacDonald
2 papers · 1 as a resident
Elizabeth Griffiths
2 papers

Clinical trials

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Site PI · Recruiting · Phase 2
Medical College of Wisconsin
2025–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027